| abstract |
The invention relates to a tumour vaccine with a tumour antigen base. In addition to a source of tumour antigens, the vaccine contains a release system for the delayed release of the active agent IFN- gamma , the active dose of IFN- gamma being 50 ng to 5 mu g. The IFN- gamma is released over a period ranging from several hours to several days. The IFN- gamma release system consists preferably of liposomes, and the tumour antigen source preferably of allogenic tumour cells. |